Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

Study: Women less likely than men to have good relief of chronic pain with long-term opioid use

Women, and especially younger women, are much less likely than men to have good relief of chronic, non-cancer pain with long-term opioid use, with only one in five women reporting low levels of pain and high levels of function with chronic opioid therapy in a new study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

9 Oct 2015

Social dynamics, family history critical to identifying patients most likely to abuse pain medicines

Patients undergoing rehabilitation for physical injuries and their physicians can better understand who is most at risk of abusing opioids by reviewing their family history, lifestyle and environment for critical cues about susceptibility to addiction, according to physical medicine and rehabilitation experts.

6 Oct 2015

Osteopathic physicians, researchers to present clinical and research updates at OMED 15

Osteopathic physicians, researchers and aligned medical professionals will present clinical and research updates in 15 specialties at OMED 15 in Orlando October 17-21.

6 Oct 2015

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

1 Oct 2015

Promising drug candidate for chronic intractable itch

If you have an itch, you have to scratch it. But that’s a problem for people with a condition called “chronic intractable itch,” where that itchy sensation never goes away—a difficult-to-treat condition closely associated with dialysis and renal failure.

28 Sep 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

New countries join ESMO Designated Centre of Integrated Oncology and Palliative Care

Patient eligibility for opioids is seriously restricted in some countries, with the highest rate of limited access to palliative care found in the Middle East, followed by Latin America and the Caribbean and Asia. Data are revealed by the ESMO Global Opioid Policy Initiative (GOPI) which identifies barriers to the availability and accessibility of essential pain relieving medication worldwide.

26 Sep 2015

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments.

25 Sep 2015

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

Once used in the 18th century as currency to reverse the trade imbalance between China and Britain, opiates that contain morphine have been misunderstood almost continually ever since.

23 Sep 2015

Study reports use of new psychoactive drugs in US nationally representative survey

In recent years, there has been an increase in emergence and use of a variety of new drugs, so-called "novel psychoactive substances" (NPS) in the US and worldwide.

16 Sep 2015

New treatment protocol can improve outcomes for babies with neonatal abstinence syndrome

A new protocol to treat babies born in withdrawal from drugs can be used widely to improve outcomes for these babies. The protocol reduces length of stay and the duration of treatment with opioids that are used therapeutically to wean babies off of drugs.

14 Sep 2015

Study shows half of adolescents misuse their prescription drugs

Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

From Quest Diagnostics 11 Sep 2015

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

Marginalized residents of Vancouver's Downtown Eastside are dying at more than eight times the national average, and treatable conditions are the greatest risk factors for mortality, researchers at the University of British Columbia have found.

11 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

AfPA’s video highlights new technology and pill formulations that deter individuals from abusing opioids

Today the Alliance for Patient Access released a new white board video, "A Prescription for Reducing Opioid Abuse." The video, released to coincide with National Pain Awareness Month, highlights new technology and innovative pill formulations that deter individuals from abusing opioids.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Opioids News and Research

Further Reading

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Study: Women less likely than men to have good relief of chronic pain with long-term opioid use

Social dynamics, family history critical to identifying patients most likely to abuse pain medicines

Osteopathic physicians, researchers to present clinical and research updates at OMED 15

Tris Pharma announces launch of generic TUSSIONEX

Promising drug candidate for chronic intractable itch

FDA accepts Braeburn's resubmission of Probuphine NDA for review

New countries join ESMO Designated Centre of Integrated Oncology and Palliative Care

New guideline on the use of prescription medications for treatment of opioid addiction

TSRI study reveals key morphine regulator that may help develop less-addictive pain medications

Study reports use of new psychoactive drugs in US nationally representative survey

New treatment protocol can improve outcomes for babies with neonatal abstinence syndrome

Study shows half of adolescents misuse their prescription drugs

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

AfPA’s video highlights new technology and pill formulations that deter individuals from abusing opioids

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News